Home Infusion Program

The Care for Rare Home Infusion Program aims to provide exactly the same level of infusion care received in hospital while improving patients’ quality of life and ensuring the quality use of medicines.

Whilst the supply of Fabrazyme will continue to be funded through the Australian Government’s Life Saving Drugs Program (LSDP) for eligible patients that meet guideline criteria, the Care for Rare Home Infusion Program will be fully funded by Sanofi Genzyme.

To learn more about patient eligibility and how to enrol Fabry patients please visit the Fabrazyme Product Site or download the Home Infusion Program Guide below or contact Sanofi Genzyme Medical Rep.